Theravance Biopharma (TBPH) is a Great Momentum Stock: Should You Buy?
Does Theravance Biopharma (TBPH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does Theravance Bio (TBPH) Have the Potential to Rally 30.64% as Wall Street Analysts Expect?
The consensus price target hints at a 30.6% upside potential for Theravance Bio (TBPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Theravance Biopharma (TBPH) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Theravance's Q3 Earnings Surpass Estimates, Revenues Match
TBPH delivers a third-quarter profit, beating estimates, and 19% revenue growth, fueled by rising collaboration income from Viatris related to Yupelri sales.
Theravance Biopharma, Inc. (TBPH) Q3 2025 Earnings Call Transcript
Theravance Biopharma, Inc. ( TBPH ) Q3 2025 Earnings Call November 10, 2025 5:00 PM EST Company Participants Rick Winningham - CEO & Director Rhonda Farnum - Chief Business Officer and Senior VP of Commercial & Medical Affairs Aine Miller - Senior VP of Development & Head of Ireland Office Aziz Sawaf - Senior VP & CFO Conference Call Participants Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division Julian Harrison - BTIG, LLC, Research Division Ellen Horste - TD Cowen, Research Division Presentation Operator Ladies and gentlemen, good afternoon.
Theravance Biopharma (TBPH) Q3 Earnings and Revenues Beat Estimates
Theravance Biopharma (TBPH) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to a loss of $0.06 per share a year ago.
Theravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue?
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?
Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
TBPH posts better-than-expected second-quarter 2025 results, boosted by Yupelri sales and licensing gains.
Theravance Biopharma, Inc. (TBPH) Q2 2025 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q2 2025 Earnings Conference Call August 12, 2025 5:00 PM ET Company Participants Aine Miller - Senior VP of Development & Head of Ireland Office Aziz Sawaf - Senior VP & CFO Rhonda F. Farnum - Chief Business Officer and Senior VP of Commercial & Medical Affairs Rick E.
Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates
Theravance Biopharma (TBPH) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.13 per share a year ago.
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises
Theravance to sell its remaining Trelegy royalty interest to GSK for $225M, with shares jumping 22% on the deal's announcement.
